팝업레이어 알림
플럼라인생명과학은 4월 23일(수) 서울대 수의대에서 신약 ‘리뉴독’을 소개했다.
반려견의 노령화는 전세계적인 현상인 반면 그 진료를 뒷받침하는 의약품은 인체용의약품에 의존하고 있다”며 “리뉴독은 동물용 DNA의약품으로는
세계 최초(First-in-Class)로 개발됐다”고 설명했다.
Plumbline Animal DNA medicines aims to unlock the full potential of global animal medicine by delivering a new class of nucleic acid-based DNA animal medicine.
DNA medicine is highly potent and safe, like mRNA medicine, and it will remain stable at room temperature for more than a year. Also, the manufacturing process of DNA plasmid is relatively simple, as it does not require the encapsulation process.
Plumbline is applying this DNA medicine platform technology to develop both companion animal therapeutics and farm animal vaccines.
